MX2010014355A - Composiciones y procedimientos de uso de la orf 554 de cepas estreptocócicas beta-hemolíticas. - Google Patents

Composiciones y procedimientos de uso de la orf 554 de cepas estreptocócicas beta-hemolíticas.

Info

Publication number
MX2010014355A
MX2010014355A MX2010014355A MX2010014355A MX2010014355A MX 2010014355 A MX2010014355 A MX 2010014355A MX 2010014355 A MX2010014355 A MX 2010014355A MX 2010014355 A MX2010014355 A MX 2010014355A MX 2010014355 A MX2010014355 A MX 2010014355A
Authority
MX
Mexico
Prior art keywords
methods
compositions
orf
beta hemolytic
ppi
Prior art date
Application number
MX2010014355A
Other languages
English (en)
Inventor
Ellen Murphy
Emily Braunstein
Annaliesa Sybil Anderson
Ingrid Lea Dodge
Original Assignee
Wyeth Llc Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc Star filed Critical Wyeth Llc Star
Publication of MX2010014355A publication Critical patent/MX2010014355A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a composiciones y métodos de uso que comprenden péptidos de peptidil-propilo isomerasa (PPI) estreptococos de los grupos C y G y polinucleótidos que codifican los mismos; la invención se refiere a composiciones inmunogénicas que comprenden los péptidos de PPI y polinucleótidos, así como a anticuerpos y fragmentos de anticuerpo que se unen a los péptidos de PPI; además, la invención se refiere a métodos de inducir una respuesta inmune en un sujeto contra estreptococos beta-hemolíticos usando las composiciones inmunogénicas, a la vez que confieren inmunidad pasiva mediante la administración de un anticuerpo o fragmento de anticuerpo terapéutico.
MX2010014355A 2008-06-20 2009-06-19 Composiciones y procedimientos de uso de la orf 554 de cepas estreptocócicas beta-hemolíticas. MX2010014355A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7423908P 2008-06-20 2008-06-20
PCT/US2009/047886 WO2009155476A2 (en) 2008-06-20 2009-06-19 Compositions and methods of use of orf 554 from beta hemolytic streptococcal strains

Publications (1)

Publication Number Publication Date
MX2010014355A true MX2010014355A (es) 2011-03-21

Family

ID=41137027

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010014355A MX2010014355A (es) 2008-06-20 2009-06-19 Composiciones y procedimientos de uso de la orf 554 de cepas estreptocócicas beta-hemolíticas.

Country Status (12)

Country Link
US (1) US7754226B2 (es)
EP (2) EP2303317A2 (es)
JP (1) JP2011525112A (es)
KR (1) KR20110031337A (es)
CN (1) CN102105165A (es)
AU (1) AU2009259951A1 (es)
BR (1) BRPI0914312A2 (es)
CA (1) CA2728258A1 (es)
IL (1) IL210068A0 (es)
MX (1) MX2010014355A (es)
RU (1) RU2010152003A (es)
WO (1) WO2009155476A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011004755A (es) * 2008-11-05 2011-10-10 Wyeth Llc Composicion inmunogenica multicomponente para la prevencion de enfermedad estreptococica beta-hemolitica (bhs).
WO2018175783A1 (en) * 2017-03-22 2018-09-27 Modernatx, Inc. Rna bacterial vaccines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03003690A (es) 2000-10-27 2004-05-05 Chiron Spa Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
IL158328A0 (en) * 2001-04-13 2004-05-12 Wyeth Corp Surface proteins of streptococcus pyogenes
AU2004218284B2 (en) * 2003-03-04 2009-07-23 Intercell Ag Streptococcus pyogenes antigens

Also Published As

Publication number Publication date
CN102105165A (zh) 2011-06-22
KR20110031337A (ko) 2011-03-25
JP2011525112A (ja) 2011-09-15
EP2650015A2 (en) 2013-10-16
IL210068A0 (en) 2011-02-28
US7754226B2 (en) 2010-07-13
AU2009259951A1 (en) 2009-12-23
WO2009155476A2 (en) 2009-12-23
WO2009155476A3 (en) 2010-03-11
BRPI0914312A2 (pt) 2017-05-30
EP2303317A2 (en) 2011-04-06
US20090318358A1 (en) 2009-12-24
RU2010152003A (ru) 2012-07-27
CA2728258A1 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
PH12021550318A1 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
MY192183A (en) Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
RU2017104529A (ru) Композиции neisseria meningitidis и способы их применения
MX351247B (es) Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
NZ585777A (en) Compositions and methods of enhancing immune responses to eimeria
CA2856895C (en) Anti-pd-l1 antibodies and uses thereof
WO2009128950A3 (en) Deletion mutants of flagellin and methods of use
SG196798A1 (en) Anti-pd-l1 antibodies and their use to enhance t-cell function
EP4272750A3 (en) Protein antigens that provide protection against pneumococcal colonization and/or disease
NZ607224A (en) Non-lipidated variants of neisseria meningitidis orf2086 antigens
EA033007B1 (ru) ПОЛИПЕПТИД, СОДЕРЖАЩИЙ ЛИПИДИРОВАННЫЙ ГЕТЕРОДИМЕР МУТАНТНЫХ ФРАГМЕНТОВ OspA, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ЕГО ПРИМЕНЕНИЯ
EA201391183A1 (ru) Способы усиления иммуногенспецифических иммунных ответов при помощи векторных вакцин
WO2005084306A3 (en) Immunogenic compositions for chlamydia pneunomiae
WO2008134643A3 (en) Trypanosoma antigens, vaccine compositions, and related methods
MX2009012777A (es) Antigenos pilus de streptococcus pneumoniae.
MX2012001495A (es) Polipeptidos de porphyromonas gingivalis.
WO2014150822A3 (en) Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
WO2008048289A3 (en) Salmonella based oral vaccines for anthrax
WO2009002418A3 (en) T-cell peptide epitopes from carcinoembryonic antigen, immunogenic analogs, and uses thereof
NZ601609A (en) Vaccine vectors and methods of enhancing immune responses
WO2007150008A3 (en) Polypeptides from african swine virus as vaccines for preventive and therapeutic use
NZ704188A (en) Attenuated swine influenza vaccines and methods of making and use thereof
FR2911608B1 (fr) Nouvelles compositions vaccinales anti paludique et ses utilisations.
NZ601980A (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same
MX2010014355A (es) Composiciones y procedimientos de uso de la orf 554 de cepas estreptocócicas beta-hemolíticas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal